

The Manager
Company Announcements Office
ASX Limited

NEWS RELEASE

HALF YEAR RESULTS

Adelaide, Australia, 16 February 2009. LabTech Systems Limited (ASX: LBT), today announced the release of its interim results for the half-year ended 31 December 2008.

Name of Entity and ACN: LabTech Systems Limited ACN 107 670 673

Reporting Period: 31 December 2008

Previous Corresponding Period: 31 December 2007

Results for announcement to the market

	2008	2007	Change	Change %
Revenue from ordinary activities	\$1,963,569	\$348,810	\$1,614,759	462.9
Profit from ordinary activities after tax attributable to members	\$739,797	(\$543,620)	\$1,283,417	Na
Profit after tax attributable to members	\$739,797	(\$544,620)	\$1,283,417	Na
Net tangible assets per security (cents)	1.27	3.17	(1.9)	(59.94)

The board will consider payment of dividends depending on future performance of the company. No dividends will be paid at this point.

Commentary on the results is provided in the Directors' report, which form part of the half year report ended 31 December 2008.

CEO and Managing Director of LabTech Systems, Lusia Guthrie, said "Both revenue and post tax profit have substantially increased as compared to the same period last year. This is a reflection of the Company's concerted efforts with its partner bioMérieux, which led to the successful launch of the PREVI™ Isola agar plate streaking machine into the global pathology markets in December 2008".

LabTech Systems does not expect any further milestone payments from bioMérieux prior to 30 June 2009. A further licence milestone payment of 2 million Euros is anticipated in 2010. The Company has reached the important step where it has now qualified to receive ongoing royalty payments on applicator sales.

--ENDS--

About LabTech Systems

LabTech Systems is an Australian developer of clinical and diagnostic technology. The company was formed in Adelaide in 2004 and listed on the Australian Securities Exchange on 31 July 2006 (ASX: LBT). In April 2007, LabTech Systems signed an agreement with French healthcare giant bioMérieux to commercialise its first product, now known as PREVI™ Isola. This is a revolutionary robotic system for the automation of microbiology processing and incorporates the breakthrough MicroStreak® technology invented at the IMVS in Adelaide and licensed to LabTech Systems.

PREVI™ Isola is a central part of bioMérieux's PREVI™ range of automated diagnostic laboratory equipment and was launched in 2008 into global pathology markets. PREVI™ Isola is currently being manufactured under licence in Melbourne and exported to global markets.

For more information, see www.labtechsystems.com and www.biomerieux.com

Contacts

LabTech Systems	Media Relations
Lusia Guthrie CEO & MD Tel: +61 (0)8 8362 2698 lusia@labtechsystems.com	Fay Weston Director, Talk Biotech Mob: 0422 206 036 fayweston@talkbiotech.com.au